Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Stockholm3 versus prostate-specific antigen in prostate cancer screening: 9-year outcomes demonstrating improved detection of aggressive cancers and reduced overdiagnosis from the STHLM3 trial
10.1016/j.eururo.2025.10.001 · 2026 · External reference
Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
10.1016/s1470-2045(15)00361-7 · 2015 · External reference
Overdiagnosis and overtreatment of prostate cancer
10.1016/j.eururo.2013.12.062 · 2014 · External reference
Biomarker: predictive or prognostic?
10.1200/jco.2015.63.3651 · 2015 · External reference
